CAREERS AT BIOMARIN
Our focus on rare disease gives us the rare opportunity to truly impact lives.
Learn More about careers with BioMarin ⌃
OUR MOTIVATION
We are inspired and driven everyday by stories like Sheri’s.
Learn More about Sheri ⌃
Patient & Community Support
Treatment is only the beginning.
We are committed to the communities we treat beyond the therapies
OUR PIPELINE
We take on the biggest challenges in rare disease.
Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it
-
May 5, 2022BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress, May 8-11, 2022, Including Five Platform Presentations
-
May 5, 2022BioMarin Hires Pharmaceutical Industry Leaders in Marketing and Accounting to Fill Strategic Roles Supporting Company’s Growth Plans
-
May 4, 2022BioMarin to Participate in the BofA Securities 2022 Healthcare Conference, Thursday, May 12 at 8:40amPT/11:40amET
-
April 27, 2022BioMarin Announces Record Revenues in First Quarter 2022
-
April 13, 2022BioMarin to Host First Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, April 27, at 4:30pm ET
-
March 17, 2022BioMarin Announces Publication in New England Journal of Medicine of One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A
-
February 23, 2022BioMarin Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates
-
February 17, 2022BioMarin Provides Updates on Progress in Gene Therapy Programs